KINE 501B
Alternative Names: KINE-501BLatest Information Update: 11 Mar 2024
At a glance
- Originator Kine Sciences
- Class Antidementias; Peptides
- Mechanism of Action Tau protein inhibitors; TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Frontotemporal dementia
Most Recent Events
- 06 Feb 2024 Early research in Frontotemporal dementia in South Korea (unspecified route) (Kine Sciences pipeline, February 2024) prior to February 2024